Pharminent

Novo gets US backing for Victoza cardiovascular data

US regulatory advisors are backing the claim that Novo Nordisks’ Victoza reduces cardiovascular risk in patients with diabetes. http://www.pharmatimes.com/news/novo_gets_us_backing_for_victoza_cardiovascular_data_1196325

Filed under: Diabetes, GLP-1

Novo files once-weekly GLP-1 analogue semaglutide

Novo Nordisk has filed its once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide with regulators on both sides of the Atlantic, seeking permission to market the drug for the treatment of adults with type II diabetes. http://www.pharmatimes.com/news/novo_files_once-weekly_glp-1_analogue_semaglutide_1180190

Filed under: Diabetes, GLP-1

FDA approves Adlyxin to treat type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513602.htm

Filed under: Diabetes, GLP-1

Novo diabetes drug cuts heart risks by 13 percent in key trial

(Reuters) – Novo Nordisk’s top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a closely watched study that may help boost sales of the injectable medicine. http://www.reuters.com/article/us-health-diabetes-novo-nordisk-idUSKCN0YZ2F7

Filed under: Diabetes, GLP-1

Now Novo Says Semaglutide Cuts CV Risk: SUSTAIN-6 Top-line Data

For the second time in just over a month, Novo Nordisk releases positive data for a GLP-1 agonist for type 2 diabetes; this time it’s for the once-weekly injection semaglutide, which is not yet approved. Medscape Medical News http://www.medscape.com/viewarticle/862644

Filed under: Diabetes, GLP-1

Novo Nordisk says Victoza helps lower heart risks

COPENHAGEN (Reuters) – Novo Nordisk said on Friday the results from a trial showed that its Victoza diabetes drug significantly reduced the risks of major adverse cardiovascular events.

http://www.reuters.com/article/us-novo-nordisk-victoza-idUSKCN0W61E1

Filed under: Diabetes, GLP-1

Novo Nordisk notches another phase 3 success for GLP-1 drug

The weekly diabetes candidate semaglutide successfully completed four prior phase 3 trials, which compared Novo’s next-gen hopeful to existing treatments.  http://www.biopharmadive.com/news/novo-nordisk-notches-another-phase-3-success-for-glp-1-drug/414525/

Filed under: Diabetes, GLP-1

Novo Nordisk announces results for SUSTAIN2 trial of semaglutide

http://www.europeanpharmaceuticalreview.com/?p=37324

Filed under: Diabetes, GLP-1

No Clear Winner Among GLP1 Agonists in Meta-Analysis

http://www.medpagetoday.com/Endocrinology/Diabetes/55069

Filed under: Diabetes, GLP-1

Lixisenatide ineffective in reducing cardiovascular events in diabetics: The ELIXA study

http://www.2minutemedicine.com/lixisenatide-ineffective-in-reducing-cardiovascular-events-in-diabetics-the-elixa-study/

Filed under: Diabetes, GLP-1

Victoza provides greater glycaemic control than SGLT-2 inhibitors

http://www.europeanpharmaceuticalreview.com/?p=37014

Filed under: Diabetes, GLP-1

New Data Show Lilly’s Once-Weekly Trulicity® (dulaglutide) is Effective as Add-on Treatment to Sulfonylurea

New Data Show Lilly’s Once-Weekly Trulicity® (dulaglutide) is Effective as Add-on Treatment to Sulfonylurea https://investor.lilly.com/releasedetail.cfm?ReleaseID=944991

Filed under: Diabetes, GLP-1

Liraglutide Delayed Type 2 Diabetes in Obese Patients with Prediabetes

http://www.endocrinologyadvisor.com/obesityweek-2015/obesity-week-liraglutide-type-2-diabetes/article/454377/

Filed under: Diabetes, GLP-1

GLP-1 receptor agonists can manage postprandial glucose

(HealthDay)—Glucagon-like peptide 1 (GLP-1) receptor agonists appear beneficial for postprandial glucose management in type 2 diabetes, according to a report published in the October issue of Clinical Diabetes. http://medicalxpress.com/news/2015-11-glp-receptor-agonists-postprandial-glucose.html

Filed under: Diabetes, GLP-1

Novo Nordisk looks to HEOR data to back Victoza

A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option for the NHS than other drugs in its class.
The findings from a health economics and outcomes research (HEOR) analysis demonstrated that Novo Nordisk’s Victoza (liraglutide) 1.2 mg is cost-effective for the treatment of type 2 diabetes in the UK market when compared to Sanofi’s Lyxumia (lixisenatide), and is cost-saving compared to Byetta (exenatide).
http://www.pharmafile.com/news/500822/novo-nordisk-looks-heor-data-back-victoza

Filed under: Diabetes, GLP-1

Victoza® (liraglutide) is cost-effective vs. lixisenatide and cost-saving vs. exenatide in the UK

http://www.prnewswire.co.uk/news-releases/victoza-liraglutide-is-cost-effective-vs-lixisenatide-and-cost-saving-vs-exenatide-in-the-uk-544586942.html

Filed under: Diabetes, GLP-1

Novo Nordisk diabetes drug fails to help heart failure: study – Reuters

Novo Nordisk diabetes drug fails to help heart failure: studyReuters”We’re disappointed this didn’t work out, but it’s important to understand heart failure and diabetes together as common problems," Dr. Adrian Hernandez, professor of medicine at Duke Clinical Research Institute and one of the study’s lead researchers …and more » http://www.reuters.com/article/2015/11/08/us-health-heart-novonordisk-idUSKCN0SX0X620151108

Filed under: Diabetes, GLP-1

Janssen Announces Global License and Development Rights Agreement with Hanmi Pharmaceutical for Novel Clinical Stage Biologic to Treat Diabetes and Obesity

Novel Oxyntomodulin-Based Therapy Bolsters Janssen’s Metabolism Portfolio  http://www.jnj.com/news/all/Janssen-Announces-Global-License-and-Development-Rights-Agreement-with-Hanmi-Pharmaceutical-for-Novel-Clinical-Stage-Biologic-to-Treat-Diabetes-and-Obesity

Filed under: Diabetes, GLP-1

Sanofi Inks $435 Million Diabetes Deal With South Korea’s Hanmi – Bloomberg

Sanofi Inks $435 Million Diabetes Deal With South Korea’s HanmiBloombergFrench drugmaker Sanofi said it entered into a licensing deal with South Korea’s Hanmi Pharmaceutical Co. Ltd, seeking to add investigational diabetes medicines to its portfolio. Under the agreement, Hanmi will receive an upfront payment of 400 million … http://www.bloomberg.com/news/articles/2015-11-05/sanofi-inks-435-million-diabetes-deal-with-south-korea-s-hanmi

Filed under: Diabetes, GLP-1

Sanofi and Hanmi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments

Sanofi will obtain an exclusive worldwide license to develop and commercialize 1.) efpeglenatide, a late-stage long-acting glucagon-like peptide-1 receptor agonists (GLP1-RA); 2.) a weekly insulin and 3.) a fixed-dosed weekly GLP-1-RA/insulin drug combination. Collectively, these therapeutic offerings are known as the “Quantum Project” utilizing Hanmi’s proprietary Long Acting Protein / Peptide Discovery Platform LAPSCOVERY technology.
http://cws.huginonline.com/S/152918/PR/201511/1964217_5.html

Filed under: Diabetes, GLP-1

Categories